Effect of calcium supplementation on bone loss in postmenopausal women

Article Abstract:

Calcium supplementation appears to reduce bone loss in postmenopausal women. Of 122 women who had reached menopause at least three years earlier, 61 took 1,000 milligrams of calcium and 61 took placebo. Years since menopause, average weight, height, physical activity, dietary calcium intake, alcohol intake and smoking habits were nearly identical in both groups. Rates of bone loss varied at different sites in the body, but overall, women taking placebo lost bone at a rate of about 1% per year. This rate of bone loss was reduced by up to 50% among women taking calcium. After two years, women taking calcium had 0.5% to 1.1% greater bone mineral density than women taking placebo. In the two-year follow-up period, there were five bone fractures among women taking placebo and two among women taking calcium.

Evaluation, Calcium (Nutrient), Calcium, Dietary

---

Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism: a randomized, controlled trial

Article Abstract:

Hormone replacement therapy appears to be effective in maintaining bone integrity in post-menopausal women with hyperparathyroidism. Bone mineral density measurements and blood and urine tests were performed on 42 post-menopausal women with hyperparathyroidism who were assigned to take either hormone replacement therapy or placebo. These measurements were repeated at both six months and two years following the start of treatment. Bone mineral density measurements increased in the treated group but decreased in the placebo group. Urine calcium levels decreased in the treated group.

Care and treatment, Physiological aspects, Hormone therapy, Hyperparathyroidism

---

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

Article Abstract:

The effects of annual infusion of zoledronic acid in postmenopausal women are assessed. This dose was found to improve the bone density and reduce the risk of osteoporotic fractures over a period of three years.

United States, Complications and side effects, Drug therapy, Dosage and administration, Osteoporosis, Zoledronic acid, Clinical report

Similar abstracts:

• Abstracts: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
• Abstracts: Calcium supplementation to prevent hypertensive disorders of pregnancy. A randomized trial of psychosocial support during high-risk pregnancies
• Abstracts: Effect of dietary energy density on total ad-libitum energy consumption by recovering malnourished children. Predictors of growth from 1 to 18 months among breast-fed Ghanaian infants
• Abstracts: Effects of oat bran concentrate on serum lipids in free-living men with mild to moderate hypercholesterolemia
• Abstracts: The effect of digital rectal examination on prostate-specific antigen levels. Disease-specific survival following routine prostate cancer screening by digital rectal examination

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.